Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04452500
PHASE2

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

Sponsor: VA Office of Research and Development

View on ClinicalTrials.gov

Summary

The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.

Official title: Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)

Key Details

Gender

All

Age Range

18 Years - 69 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2022-10-15

Completion Date

2026-12-31

Last Updated

2026-01-29

Healthy Volunteers

No

Conditions

Interventions

DRUG

CORT108297

CORT108297- 180mg daily for 7 days

DRUG

Placebo

Placebo- 180mg daily for 7 days

Locations (2)

Tuscaloosa VA Medical Center, Tuscaloosa, AL

Tuscaloosa, Alabama, United States

San Francisco VA Medical Center, San Francisco, CA

San Francisco, California, United States